UCB Soars to Record as Rival MoonLake Crashes on Trial Data
Yahoo Finance·2025-09-29 21:42
Shares in Belgium’s UCB SA soared to a record, while rival MoonLake Immunotherapeutics lost most of its value, after the latter announced late-stage trial data for an experimental skin disease drug that analysts said failed to demonstrate superiority to one of UCB’s most important medicines. UCB shares surged as much as 20%, adding more than €7 billion (4 billion capitalization. Most Read from Bloom ...